Interim Reports
Latest Reports
Interim Report 1 2023/24
During this past summer quarter, we made it our most prosperous Q1 quarter to date, characterized by sustained growth.
Learn more …
Interim Report 4 2022/23
Sales continue to grow, and the year ended up with the highest turnover for a year in PHI, so far.
Learn more …
Interim Report 3 2022/23
Sales have continued to grow, with significantly higher cost efficiency. As a result, rolling 12-month sales gained to its highest level ever.
Learn more …
Interim Report 2 2022/23
The online sales and lead generation strategy continues to deliver. As a result, sales from August to October this year reached 2.7 KSEK — an increase of 50 % compared to any previous corresponding period.
Learn more …
Interim Report 1 2022/23
Despite a summer-sluggish period ending in July, sales were just one unit away from surpassing our best quarter ever; the same period last year.
Learn more …
Year-end Report 2021/22
Sales more than doubled in 2021/22, compared to previous financial year.
Learn more …
Interim Report 2 2021/22
Strong sales growth for the 3rd consecutive quarter. Recent advancements in regenerative medicine create additional growth potential in clinical applications for the company.
Learn more …